Company Overview

PRIME exits and American Healthcare Capital are pleased to exclusively introduce an innovative MedTech developer that has created a technology breakthrough, patent-protected non-invasive, long-term pain management medical device to reduce pain caused by joint inflammation while promoting the process of tissue regeneration through a dedicated tissue regeneration device. The device improves daily function and performance, creating pain-free living. For the first time, both inflammation reduction and tissue restoration are addressed using a combination of electrical and thermal stimulation. This is a true breakthrough in pain management.

Financial Overview

The pain management with remote therapeutic monitoring company has ended its pre-revenue stage and has begun selling its first in a line of joint-specific products for treatment of pain and OA. The sales of its current device are “proof of concept” for the development and launch of the Next Generation of products in 2025 and 2026. The new devices under development have widespread use with advanced technology and maintain high gross profit margins. The channels of distribution for these pain management devices are huge with expected coverage in Integrated Group Clinical Practices, Chiropractic and Physical Therapy Practices and all areas of wellness settings. The Company is forecasting $16.6 million in revenues in 2027 with an Adjusted EBITDA of $4.9 million (29%).

Asking Price

The Company is looking for a strategic or financial partner to add value through its connections, financial strength, and resources to grow the Company to the next level. Therefore, the founders will consider a buyout in support of the future growth potential for this innovative technology platform.